Cargando…
Application of cross-species PET imaging to assess neurotransmitter release in brain
RATIONALE: This review attempts to summarize the current status in relation to the use of positron emission tomography (PET) imaging in the assessment of synaptic concentrations of endogenous mediators in the living brain. OBJECTIVES: Although PET radioligands are now available for more than 40 CNS...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4600473/ https://www.ncbi.nlm.nih.gov/pubmed/25921033 http://dx.doi.org/10.1007/s00213-015-3938-6 |
_version_ | 1782394424720883712 |
---|---|
author | Finnema, Sjoerd J. Scheinin, Mika Shahid, Mohammed Lehto, Jussi Borroni, Edilio Bang-Andersen, Benny Sallinen, Jukka Wong, Erik Farde, Lars Halldin, Christer Grimwood, Sarah |
author_facet | Finnema, Sjoerd J. Scheinin, Mika Shahid, Mohammed Lehto, Jussi Borroni, Edilio Bang-Andersen, Benny Sallinen, Jukka Wong, Erik Farde, Lars Halldin, Christer Grimwood, Sarah |
author_sort | Finnema, Sjoerd J. |
collection | PubMed |
description | RATIONALE: This review attempts to summarize the current status in relation to the use of positron emission tomography (PET) imaging in the assessment of synaptic concentrations of endogenous mediators in the living brain. OBJECTIVES: Although PET radioligands are now available for more than 40 CNS targets, at the initiation of the Innovative Medicines Initiative (IMI) “Novel Methods leading to New Medications in Depression and Schizophrenia” (NEWMEDS) in 2009, PET radioligands sensitive to an endogenous neurotransmitter were only validated for dopamine. NEWMEDS work-package 5, “Cross-species and neurochemical imaging (PET) methods for drug discovery”, commenced with a focus on developing methods enabling assessment of changes in extracellular concentrations of serotonin and noradrenaline in the brain. RESULTS: Sharing the workload across institutions, we utilized in vitro techniques with cells and tissues, in vivo receptor binding and microdialysis techniques in rodents, and in vivo PET imaging in non-human primates and humans. Here, we discuss these efforts and review other recently published reports on the use of radioligands to assess changes in endogenous levels of dopamine, serotonin, noradrenaline, γ-aminobutyric acid, glutamate, acetylcholine, and opioid peptides. The emphasis is on assessment of the availability of appropriate translational tools (PET radioligands, pharmacological challenge agents) and on studies in non-human primates and human subjects, as well as current challenges and future directions. CONCLUSIONS: PET imaging directed at investigating changes in endogenous neurochemicals, including the work done in NEWMEDS, have highlighted an opportunity to further extend the capability and application of this technology in drug development. |
format | Online Article Text |
id | pubmed-4600473 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-46004732015-10-16 Application of cross-species PET imaging to assess neurotransmitter release in brain Finnema, Sjoerd J. Scheinin, Mika Shahid, Mohammed Lehto, Jussi Borroni, Edilio Bang-Andersen, Benny Sallinen, Jukka Wong, Erik Farde, Lars Halldin, Christer Grimwood, Sarah Psychopharmacology (Berl) Review RATIONALE: This review attempts to summarize the current status in relation to the use of positron emission tomography (PET) imaging in the assessment of synaptic concentrations of endogenous mediators in the living brain. OBJECTIVES: Although PET radioligands are now available for more than 40 CNS targets, at the initiation of the Innovative Medicines Initiative (IMI) “Novel Methods leading to New Medications in Depression and Schizophrenia” (NEWMEDS) in 2009, PET radioligands sensitive to an endogenous neurotransmitter were only validated for dopamine. NEWMEDS work-package 5, “Cross-species and neurochemical imaging (PET) methods for drug discovery”, commenced with a focus on developing methods enabling assessment of changes in extracellular concentrations of serotonin and noradrenaline in the brain. RESULTS: Sharing the workload across institutions, we utilized in vitro techniques with cells and tissues, in vivo receptor binding and microdialysis techniques in rodents, and in vivo PET imaging in non-human primates and humans. Here, we discuss these efforts and review other recently published reports on the use of radioligands to assess changes in endogenous levels of dopamine, serotonin, noradrenaline, γ-aminobutyric acid, glutamate, acetylcholine, and opioid peptides. The emphasis is on assessment of the availability of appropriate translational tools (PET radioligands, pharmacological challenge agents) and on studies in non-human primates and human subjects, as well as current challenges and future directions. CONCLUSIONS: PET imaging directed at investigating changes in endogenous neurochemicals, including the work done in NEWMEDS, have highlighted an opportunity to further extend the capability and application of this technology in drug development. Springer Berlin Heidelberg 2015-04-30 2015 /pmc/articles/PMC4600473/ /pubmed/25921033 http://dx.doi.org/10.1007/s00213-015-3938-6 Text en © The Author(s) 2015 |
spellingShingle | Review Finnema, Sjoerd J. Scheinin, Mika Shahid, Mohammed Lehto, Jussi Borroni, Edilio Bang-Andersen, Benny Sallinen, Jukka Wong, Erik Farde, Lars Halldin, Christer Grimwood, Sarah Application of cross-species PET imaging to assess neurotransmitter release in brain |
title | Application of cross-species PET imaging to assess neurotransmitter release in brain |
title_full | Application of cross-species PET imaging to assess neurotransmitter release in brain |
title_fullStr | Application of cross-species PET imaging to assess neurotransmitter release in brain |
title_full_unstemmed | Application of cross-species PET imaging to assess neurotransmitter release in brain |
title_short | Application of cross-species PET imaging to assess neurotransmitter release in brain |
title_sort | application of cross-species pet imaging to assess neurotransmitter release in brain |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4600473/ https://www.ncbi.nlm.nih.gov/pubmed/25921033 http://dx.doi.org/10.1007/s00213-015-3938-6 |
work_keys_str_mv | AT finnemasjoerdj applicationofcrossspeciespetimagingtoassessneurotransmitterreleaseinbrain AT scheininmika applicationofcrossspeciespetimagingtoassessneurotransmitterreleaseinbrain AT shahidmohammed applicationofcrossspeciespetimagingtoassessneurotransmitterreleaseinbrain AT lehtojussi applicationofcrossspeciespetimagingtoassessneurotransmitterreleaseinbrain AT borroniedilio applicationofcrossspeciespetimagingtoassessneurotransmitterreleaseinbrain AT bangandersenbenny applicationofcrossspeciespetimagingtoassessneurotransmitterreleaseinbrain AT sallinenjukka applicationofcrossspeciespetimagingtoassessneurotransmitterreleaseinbrain AT wongerik applicationofcrossspeciespetimagingtoassessneurotransmitterreleaseinbrain AT fardelars applicationofcrossspeciespetimagingtoassessneurotransmitterreleaseinbrain AT halldinchrister applicationofcrossspeciespetimagingtoassessneurotransmitterreleaseinbrain AT grimwoodsarah applicationofcrossspeciespetimagingtoassessneurotransmitterreleaseinbrain |